Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
GlobeNewswire
· Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals..